CR20110358A - Proteinas de enlace de miostatina - Google Patents

Proteinas de enlace de miostatina

Info

Publication number
CR20110358A
CR20110358A CR20110358A CR20110358A CR20110358A CR 20110358 A CR20110358 A CR 20110358A CR 20110358 A CR20110358 A CR 20110358A CR 20110358 A CR20110358 A CR 20110358A CR 20110358 A CR20110358 A CR 20110358A
Authority
CR
Costa Rica
Prior art keywords
mythatin
link proteins
antigen binding
binding proteins
proteins
Prior art date
Application number
CR20110358A
Other languages
English (en)
Inventor
Claire Ashman
Andrew Beaton
Jonathan Henry Ellis
Bajin Han
Ian Kirby
Frederick Kull
Alan Lewis
Kathryn Mason Lindley
Martin Anibal Orecchia
Ying Shen
Paul Wilson
Tian Shun Xu
Hong Zhang
Original Assignee
Trius Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786068&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110358(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trius Therapeutics filed Critical Trius Therapeutics
Publication of CR20110358A publication Critical patent/CR20110358A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se describen proteínas de enlace de antígeno, tales como anticuerpos, que se enlazan a la miostatina, polinucleótidos que codifican estas proteínas de enlace de antígeno, composiciones farmacéuticas que comprenden estas proteínas de enlace de antígeno, y métodos para su elaboración.
CR20110358A 2008-12-19 2011-06-23 Proteinas de enlace de miostatina CR20110358A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13898008P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
CR20110358A true CR20110358A (es) 2011-10-04

Family

ID=41786068

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110358A CR20110358A (es) 2008-12-19 2011-06-23 Proteinas de enlace de miostatina

Country Status (24)

Country Link
US (1) US20110256132A1 (es)
EP (1) EP2358753A1 (es)
JP (1) JP2012512641A (es)
KR (1) KR20110103431A (es)
CN (1) CN102325793A (es)
AR (1) AR074777A1 (es)
AU (1) AU2009329533A1 (es)
BR (1) BRPI0922405A2 (es)
CA (1) CA2747062A1 (es)
CL (1) CL2011001503A1 (es)
CO (1) CO6400149A2 (es)
CR (1) CR20110358A (es)
DO (1) DOP2011000189A (es)
EA (1) EA201190018A1 (es)
IL (1) IL213243A0 (es)
MA (1) MA32980B1 (es)
MX (1) MX2011006611A (es)
NZ (1) NZ593297A (es)
PE (1) PE20120429A1 (es)
SG (1) SG172039A1 (es)
TW (1) TW201029662A (es)
UY (1) UY32341A (es)
WO (1) WO2010070094A1 (es)
ZA (1) ZA201104397B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP4238993A3 (en) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
BR112013030352B1 (pt) * 2011-06-02 2020-05-19 Dyax Corp anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
WO2013074557A1 (en) 2011-11-14 2013-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
TWI697501B (zh) 2012-08-24 2020-07-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
CN104768969B (zh) * 2012-09-13 2021-04-16 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
JP6706617B2 (ja) 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3394098A4 (en) * 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
PT3368069T (pt) 2016-06-13 2020-11-11 Scholar Rock Inc Uso de inibidores da miostatina e terapias de combinação
MY193497A (en) * 2016-06-17 2022-10-17 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
FR3055548B1 (fr) * 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
PT3565592T (pt) * 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina
ES2944357T3 (es) * 2017-01-06 2023-06-20 Scholar Rock Inc Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
MX2020008991A (es) 2018-03-01 2020-12-10 Regeneron Pharma Metodos para alterar la composicion corporal.
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
WO2023069605A1 (en) * 2021-10-20 2023-04-27 Arizona Board Of Regents On Behalf Of Arizona State University Systems, methods, and apparatuses for implementing a cloud-based health, nutritional, and body composition analysis platform
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
EP1333035A3 (en) 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
EP0969862B1 (en) 1997-02-07 2006-10-18 Merck & Co., Inc. Synthetic hiv gag genes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
CN1555411A (zh) 2001-08-03 2004-12-15 ���迨�����＼���ɷݹ�˾ 抗体-依赖性细胞毒性增大的抗体糖基化变体
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
JP4871126B2 (ja) 2003-07-04 2012-02-08 アフィボディ・アーベー Ｈｅｒ２に対する結合親和性を有するポリペプチド
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
WO2005094446A2 (en) 2004-03-23 2005-10-13 Eli Lilly And Company Anti-myostatin antibodies
EP1776385A1 (en) 2004-07-21 2007-04-25 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
GB0425555D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
MX2007013217A (es) * 2005-04-25 2008-03-11 Pfizer Anticuerpos contra miostatina.
JP5249751B2 (ja) 2005-05-20 2013-07-31 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規方法
CN103450359B (zh) * 2005-08-19 2018-07-24 惠氏有限责任公司 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
EP1951756B1 (en) 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
PT2066695E (pt) 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety

Also Published As

Publication number Publication date
CL2011001503A1 (es) 2012-02-03
WO2010070094A1 (en) 2010-06-24
IL213243A0 (en) 2011-07-31
EA201190018A1 (ru) 2013-02-28
CN102325793A (zh) 2012-01-18
MX2011006611A (es) 2011-06-30
KR20110103431A (ko) 2011-09-20
NZ593297A (en) 2012-10-26
PE20120429A1 (es) 2012-05-08
JP2012512641A (ja) 2012-06-07
MA32980B1 (fr) 2012-01-02
AU2009329533A1 (en) 2011-06-30
SG172039A1 (en) 2011-07-28
CA2747062A1 (en) 2010-06-24
BRPI0922405A2 (pt) 2018-10-23
TW201029662A (en) 2010-08-16
UY32341A (es) 2010-07-30
AR074777A1 (es) 2011-02-09
EP2358753A1 (en) 2011-08-24
DOP2011000189A (es) 2011-07-31
CO6400149A2 (es) 2012-03-15
ZA201104397B (en) 2012-11-28
US20110256132A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
CR20110358A (es) Proteinas de enlace de miostatina
CR20130128A (es) Nuevas proteínas de unión a antígenos
ECSP11011445A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
CO7250445A2 (es) Proteínas de unión a antígeno st2
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
BR112013029893A2 (pt) molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
BR112015012933A2 (pt) proteínas de ligação ao antígeno bcma
ECSP13012649A (es) Anticuerpos ANTI-IL-23
EA201790757A1 (ru) Связывающие антиген cd27l белки
CY1122978T1 (el) Αντισωματα εναντι-vla-4
ECSP14004976A (es) Anticuerpos anti-il-36r
MX2012007340A (es) Anticuerpos anti/her3 y usos de los mismos.
UY33319A (es) PROTEÍNAS QUE SE UNEN AL TNF-a
AR088512A1 (es) Anticuerpos dirigidos contra el tnf
CL2013000338A1 (es) Proteina de union que tiene la capacidad de unirse a interleuquina 1beta y a la interleuquina 17; conjugado de proteina de union cristalizada; acido nucleico, vector, célula huesped; metodo para producir una proteina de unión; composicion farmacéutica que comprende la proteina de unión.
WO2010145792A8 (en) Bispecific antigen binding proteins
BRPI1006141A2 (pt) composições de anticorpo modificado, métodos para preparar e usar as mesmas
CR20110400A (es) Proteinas de enlace al receptor cgrp humano
AR070453A1 (es) Anticuerpos dirigidos a angiopoyetina -1 y angiopoyetina-2 y usos de los mismos
BRPI1011043A2 (pt) compostos de fenilureias e fenilamidas substituídas como ligantes de receptor de vaniloide, sua composição farmacêutica, seu uso e seu processo de preparação.
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
AR090923A1 (es) Anticuerpos anti-il-23
UY33274A (es) Proteínas de unión a basigina
EA201500502A1 (ru) Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3
CR20150195A (es) Proteínas ligantes de antígeno anti-her3/her4 de unión a la horquilla beta de her3 y la horquilla beta de her4